Celldom, Inc Stock

Find and study cells that make diseases incurable

Sign up today and learn more about Celldom, Inc Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Celldom, Inc Stock

Celldom is developing next generation, high throughput single cell analysis technology to advance research, drug discovery, and drug development by illuminating diversity in cell populations. The company’s TrapTx Analyzer System uniquely integrates both phenotypic and genomic data at massive scale (up to tens of thousands of cells per experiment) to identify and characterize rare cells that play critical roles in biological pathways and disease. Celldom is developing initial applications of the platform in the areas of oncology, immunology and stem cell biology.

Funding History

January 2017$225K
December 2017$225K
September 2018$1.5M


Commercial Advisor

J. Kurt Jacobus

Scientific & Commercial Advisor

Myla Lai-Goldman

Technical Advisor - Systems Engineering

Emil Radulescu

Financial Advisor

Jeff Blake

Co-Founder, Chief Executive Officer

Benjamin Yellen

Co-Founder, President, & CEO

Zachary Forbes


Kris Wood

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: